<p>根据最近向证券交易委员会（SEC）披露的信息，Acadian Asset Management LLC 在 2023 年第一季度将其在 Dr. Reddy's Laboratories Ltd（纽约证券交易所代码：RDY - 免费报告）的股份增加了 1.6%。该基金在本季度额外收购了 23,582 股后，持有该公司 1,471,523 股股票。截至其最近的 SEC 文件，Acadian Asset Management LLC 持有的 Dr. Reddy's Laboratories 的股份约占 0.18%，价值 1,940 万美元。</p>
<ul>
<li>Teva Pharmaceuticals 股票：发掘这款仿制药的价值</li>
</ul>
<p>其他几家大型投资者最近也增加或减少了在 RDY 的持股。美国银行（Bank of America Corp DE）在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 123.1%。美国银行目前持有该公司 1,916,425 股股票，价值 3,026 万美元，此前在上个季度额外收购了 1,057,584 股。Cetera Investment Advisers 在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 410.5%。Cetera Investment Advisers 目前持有该公司 20,720 股股票，价值 32.7 万美元，此前在上个季度额外收购了 16,661 股。D. E. Shaw &amp; Co. Inc.在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 256.3%。D. E. Shaw &amp; Co. Inc.目前持有该公司 429,887 股股票，价值 678.8 万美元，此前在上个季度额外收购了 309,239 股。德意志银行（Deutsche Bank AG）在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 311.9%。德意志银行目前持有该公司 171,602 股股票，价值 271 万美元，此前在上个季度额外收购了 129,936 股。最后，Ethic Inc.在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 422.2%。Ethic Inc.目前持有该公司 23,073 股股票，价值 36.4 万美元，此前在上个季度额外收购了 18,655 股。机构投资者持有该股票的 3.85%。</p>
<h2>Dr. Reddy's Laboratories 股票上涨 1.0%</h2>
<p>周五，NYSE RDY 的股票开盘价为 14.72 美元。该公司的债务与股本比率为 0.01，速动比率为 1.36，流动比率为 1.89。该公司的市值为 122.9 亿美元，市盈率为 22.30，PEG 比率为 5.89，贝塔值为 0.32。该股票的 50 日移动平均价格为 14.34 美元，200 日移动平均价格为 14.09 美元。Dr. Reddy's Laboratories Ltd 的 52 周低点为 12.26 美元，52 周高点为 16.19 美元。</p>
<ul>
<li>2 只被忽视的股票，盈利却下跌</li>
</ul>
<p>Dr. Reddy's Laboratories（NYSE:RDY - 获取免费报告）最近一次发布财报是在 7 月 23 日，报告显示该季度每股收益为 0.20 美元，超出分析师一致预期的 0.18 美元，超出幅度为 0.02 美元。该季度的收入为 9.8882 亿美元，而分析师预期为 882.7 亿美元。Dr. Reddy's Laboratories 的股本回报率为 17.25%，净利润率为 16.99%。卖方分析师预计 Dr. Reddy's Laboratories Ltd 在当前年度的每股收益将为 0.8 美元。</p>
<h2>Dr. Reddy's Laboratories 增加股息</h2>
<p>该公司最近还宣布了一项年度股息，于 8 月 6 日支付。7 月 10 日的股东获得每股 0.0915 美元的股息。这比 Dr. Reddy's Laboratories 之前的年度股息 0.08 美元有所增加，代表 62.4% 的收益率。除息日期为 7 月 25 日。Dr. Reddy's Laboratories 的股息支付比率（DPR）目前为 10.61%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>制药公司 GSK：成为更健康的价值股</li>
</ul>
<p>多家研究机构最近对 RDY 发表了评论。汇丰银行（HSBC）将 Dr. Reddy's Laboratories 的评级从 “持有” 上调至 “买入”，并在 6 月 5 日的研究报告中将其目标价从 14.44 美元上调至 16.90 美元。汇丰全球研究（Hsbc Global Res）在 6 月 5 日的研究报告中将 Dr. Reddy's Laboratories 的评级从 “持有” 上调至 “强烈买入”。最后，Zacks Research 在 8 月 15 日的研究报告中将 Dr. Reddy's Laboratories 的评级从 “强烈卖出” 上调至 “持有”。一位投资分析师给予该股票 “强烈买入” 评级，两位给予 “买入” 评级，两位给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 16.95 美元。</p>
<p><strong>阅读我们对 RDY 的最新分析</strong></p>
<h2>关于 Dr. Reddy's Laboratories</h2>
<p>（免费报告）</p>
<p>Dr. Reddy's Laboratories Limited 及其子公司在全球范围内作为一家综合制药公司运营。它通过全球仿制药、制药服务和活性成分（PSAI）及其他部门运营。该公司的全球仿制药部门生产和销售处方药和非处方成品药，这些药物以品牌名称或作为具有治疗等效性的仿制成品剂型进行市场营销，同时还参与生物制药业务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Dr. Reddy's Laboratories</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>接近阻力位的高飞股票：3 只值得关注的股票</li>
<li>2 只上升的 CRM 平台股票，预计在 2025 年将大幅上涨</li>
<li>希捷科技在标准普尔 500 中领先：其 120% 涨幅背后的原因是什么？</li>
<li>什么是成长股及其投资方式</li>
<li>先锋集团的 VUG ETF：您投资组合的终极成长 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJEWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJEWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

如瑞迪博士

<p>Acadian Asset Management LLC 在第一季度将其在药明康德（NYSE:RDY）的持股增加了 1.6%，额外购买了 23,582 股，总持股达到 1,471,523 股，价值 1,940 万美元。包括美国银行和德意志银行在内的其他投资者也显著增加了他们的持股。药明康德的股票开盘价为 14.72 美元，市值为 122.9 亿美元。该公司最近宣布了股息增加，并获得了多家研究机构的评级上调，普遍评级为 “适度买入”，平均目标价为 16.95 美元</p>

<p>Acadian Asset Management LLC boosted its stake in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 1.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,471,523 shares of the company's stock after acquiring an additional 23,582 shares during the quarter. Acadian Asset Management LLC owned about 0.18% of Dr. Reddy's Laboratories worth $19,404,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）披露的信息，Acadian Asset Management LLC 在 2023 年第一季度将其在 Dr. Reddy's Laboratories Ltd（纽约证券交易所代码：RDY - 免费报告）的股份增加了 1.6%。该基金在本季度额外收购了 23,582 股后，持有该公司 1,471,523 股股票。截至其最近的 SEC 文件，Acadian Asset Management LLC 持有的 Dr. Reddy's Laboratories 的股份约占 0.18%，价值 1,940 万美元。</p>
</div><ul>
<li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharmaceuticals 股票：发掘这款仿制药的价值</li>
</ul>
</div><p>Several other large investors also recently added to or reduced their stakes in RDY. Bank of America Corp DE increased its stake in Dr. Reddy's Laboratories by 123.1% during the fourth quarter. Bank of America Corp DE now owns 1,916,425 shares of the company's stock worth $30,260,000 after acquiring an additional 1,057,584 shares during the last quarter. Cetera Investment Advisers increased its stake in Dr. Reddy's Laboratories by 410.5% during the fourth quarter. Cetera Investment Advisers now owns 20,720 shares of the company's stock worth $327,000 after acquiring an additional 16,661 shares during the last quarter. D. E. Shaw &amp; Co. Inc. increased its stake in Dr. Reddy's Laboratories by 256.3% during the fourth quarter. D. E. Shaw &amp; Co. Inc. now owns 429,887 shares of the company's stock worth $6,788,000 after acquiring an additional 309,239 shares during the last quarter. Deutsche Bank AG increased its stake in Dr. Reddy's Laboratories by 311.9% during the fourth quarter. Deutsche Bank AG now owns 171,602 shares of the company's stock worth $2,710,000 after acquiring an additional 129,936 shares during the last quarter. Finally, Ethic Inc. grew its stake in shares of Dr. Reddy's Laboratories by 422.2% during the fourth quarter. Ethic Inc. now owns 23,073 shares of the company's stock valued at $364,000 after buying an additional 18,655 shares during the last quarter. 3.85% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了在 RDY 的持股。美国银行（Bank of America Corp DE）在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 123.1%。美国银行目前持有该公司 1,916,425 股股票，价值 3,026 万美元，此前在上个季度额外收购了 1,057,584 股。Cetera Investment Advisers 在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 410.5%。Cetera Investment Advisers 目前持有该公司 20,720 股股票，价值 32.7 万美元，此前在上个季度额外收购了 16,661 股。D. E. Shaw &amp; Co. Inc.在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 256.3%。D. E. Shaw &amp; Co. Inc.目前持有该公司 429,887 股股票，价值 678.8 万美元，此前在上个季度额外收购了 309,239 股。德意志银行（Deutsche Bank AG）在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 311.9%。德意志银行目前持有该公司 171,602 股股票，价值 271 万美元，此前在上个季度额外收购了 129,936 股。最后，Ethic Inc.在第四季度将其在 Dr. Reddy's Laboratories 的股份增加了 422.2%。Ethic Inc.目前持有该公司 23,073 股股票，价值 36.4 万美元，此前在上个季度额外收购了 18,655 股。机构投资者持有该股票的 3.85%。</p>
</div><h2>Dr. Reddy's Laboratories Stock Up 1.0%</h2>
<div class="lb-trans"><h2>Dr. Reddy's Laboratories 股票上涨 1.0%</h2>
</div><p>Shares of NYSE RDY opened at $14.72 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.36 and a current ratio of 1.89. The firm has a market capitalization of $12.29 billion, a price-to-earnings ratio of 22.30, a PEG ratio of 5.89 and a beta of 0.32. The stock has a 50 day moving average price of $14.34 and a 200 day moving average price of $14.09. Dr. Reddy's Laboratories Ltd has a 52-week low of $12.26 and a 52-week high of $16.19.</p>
<div class="lb-trans"><p>周五，NYSE RDY 的股票开盘价为 14.72 美元。该公司的债务与股本比率为 0.01，速动比率为 1.36，流动比率为 1.89。该公司的市值为 122.9 亿美元，市盈率为 22.30，PEG 比率为 5.89，贝塔值为 0.32。该股票的 50 日移动平均价格为 14.34 美元，200 日移动平均价格为 14.09 美元。Dr. Reddy's Laboratories Ltd 的 52 周低点为 12.26 美元，52 周高点为 16.19 美元。</p>
</div><ul>
<li>2 overlooked stocks that crushed earnings but traded lower</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只被忽视的股票，盈利却下跌</li>
</ul>
</div><p>Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The company had revenue of $988.82 million during the quarter, compared to analyst estimates of $88.27 billion. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. Sell-side analysts expect that Dr. Reddy's Laboratories Ltd will post 0.8 earnings per share for the current year.</p>
<div class="lb-trans"><p>Dr. Reddy's Laboratories（NYSE:RDY - 获取免费报告）最近一次发布财报是在 7 月 23 日，报告显示该季度每股收益为 0.20 美元，超出分析师一致预期的 0.18 美元，超出幅度为 0.02 美元。该季度的收入为 9.8882 亿美元，而分析师预期为 882.7 亿美元。Dr. Reddy's Laboratories 的股本回报率为 17.25%，净利润率为 16.99%。卖方分析师预计 Dr. Reddy's Laboratories Ltd 在当前年度的每股收益将为 0.8 美元。</p>
</div><h2>Dr. Reddy's Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>Dr. Reddy's Laboratories 增加股息</h2>
</div><p>The business also recently announced an annual dividend, which was paid on Wednesday, August 6th. Shareholders of record on Thursday, July 10th were issued a dividend of $0.0915 per share. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.08. This represents a yield of 62.4%. The ex-dividend date was Friday, July 25th. Dr. Reddy's Laboratories's dividend payout ratio (DPR) is currently 10.61%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项年度股息，于 8 月 6 日支付。7 月 10 日的股东获得每股 0.0915 美元的股息。这比 Dr. Reddy's Laboratories 之前的年度股息 0.08 美元有所增加，代表 62.4% 的收益率。除息日期为 7 月 25 日。Dr. Reddy's Laboratories 的股息支付比率（DPR）目前为 10.61%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Drugmaker GSK: Becoming a Healthier Value Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>制药公司 GSK：成为更健康的价值股</li>
</ul>
</div><p>A number of research firms have recently commented on RDY. HSBC raised Dr. Reddy's Laboratories from a &#34;hold&#34; rating to a &#34;buy&#34; rating and upped their target price for the company from $14.44 to $16.90 in a research note on Thursday, June 5th. Hsbc Global Res raised Dr. Reddy's Laboratories from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, June 5th. Finally, Zacks Research raised Dr. Reddy's Laboratories from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $16.95.</p>
<div class="lb-trans"><p>多家研究机构最近对 RDY 发表了评论。汇丰银行（HSBC）将 Dr. Reddy's Laboratories 的评级从 “持有” 上调至 “买入”，并在 6 月 5 日的研究报告中将其目标价从 14.44 美元上调至 16.90 美元。汇丰全球研究（Hsbc Global Res）在 6 月 5 日的研究报告中将 Dr. Reddy's Laboratories 的评级从 “持有” 上调至 “强烈买入”。最后，Zacks Research 在 8 月 15 日的研究报告中将 Dr. Reddy's Laboratories 的评级从 “强烈卖出” 上调至 “持有”。一位投资分析师给予该股票 “强烈买入” 评级，两位给予 “买入” 评级，两位给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 16.95 美元。</p>
</div><p><strong>Read Our Latest Analysis on RDY</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 RDY 的最新分析</strong></p>
</div><h2>About Dr. Reddy's Laboratories</h2>
<div class="lb-trans"><h2>关于 Dr. Reddy's Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.</p>
<div class="lb-trans"><p>Dr. Reddy's Laboratories Limited 及其子公司在全球范围内作为一家综合制药公司运营。它通过全球仿制药、制药服务和活性成分（PSAI）及其他部门运营。该公司的全球仿制药部门生产和销售处方药和非处方成品药，这些药物以品牌名称或作为具有治疗等效性的仿制成品剂型进行市场营销，同时还参与生物制药业务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Dr. Reddy's Laboratories</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Dr. Reddy's Laboratories</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>接近阻力位的高飞股票：3 只值得关注的股票</li>
<li>2 只上升的 CRM 平台股票，预计在 2025 年将大幅上涨</li>
<li>希捷科技在标准普尔 500 中领先：其 120% 涨幅背后的原因是什么？</li>
<li>什么是成长股及其投资方式</li>
<li>先锋集团的 VUG ETF：您投资组合的终极成长 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJEWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=RDY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Dr. Reddy's Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在药明康德吗？</h2>
</div><p>Before you consider Dr. Reddy's Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而药明康德并不在名单上。</p>
</div><p>While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Acadian Asset Management LLC 购买了 23,582 股 Dr Reddys Laboratories Ltd 的股票$RDY